Background: To evaluate factors which effect treatment interruption during concurrent chemoradiotherapy(CCRT) and overall survival in patients with uterine cervical cancer stage IB2-IVA in Srinagarind Hospital.Materials and Methods: Between January 2006 and December 2007, 107 patients with stage IB2-IVA as FIGOstaging, 2000, were treated with CCRT in Srinagarind Hospital. Factors which caused treatment interruptionsand impacted on overall survival were reviewed and analyzed. Results: Twenty of 107 patients had treatmentinterruption during CCRT in patients with uterine cervical cancer stage IB2-IVA in Srinagarind Hospital. Thecauses of treatment interruption were as follows: hematologic toxicity was found in 16 of 20 cases, 12 cases withgrade 2 and 4 cases with grade 3; three of 20 cases had gastrointestinal toxicities, 1 case with grade 2 and 2cases with grade 3; one case had grade 3 skin toxicity. The mean total treatment time of the uninterrupted andinterrupted groups were significantly different (78.98 days vs 161.80 days, p <0.001). The patients who couldtolerate≥5 cycles of cisplatin administration had significantly higher mean white blood counts (WBC) (9,769 cells/mm3 vs 7,141 cells/mm3, p=0.02). The mean initial hemoglobin (Hb) in the uninterrupted group was significantlyhigher than the interrupted group (11.5 mg% vs 10.3 mg%, p=0.03). Other factors including age, KPS, initialplatelets, initial serum creatinine levels showed no statistical significance. The 3-year overall survival of theuninterrupted group was better than in the interrupted group (78.6% vs 55.0%, p=0.03). Conclusions: Theinitial Hb and WBC levels were significantly correlated with treatment interruption during CCRT in patientswith uterine cervical cancer. The 3-year overall survival of the uninterrupted group was significantly better thaninterrupted group. These factors may then be used indirectly to predict the outcomes of treatment.
(2014). Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes. Asian Pacific Journal of Cancer Prevention, 15(14), 5653-5657.
MLA
. "Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes". Asian Pacific Journal of Cancer Prevention, 15, 14, 2014, 5653-5657.
HARVARD
(2014). 'Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes', Asian Pacific Journal of Cancer Prevention, 15(14), pp. 5653-5657.
VANCOUVER
Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes. Asian Pacific Journal of Cancer Prevention, 2014; 15(14): 5653-5657.